Omics, Bioinformatics and Flow Cytometry Core
组学、生物信息学和流式细胞术核心
基本信息
- 批准号:10630580
- 负责人:
- 金额:$ 22.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-15 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:African American populationApoptosisBioinformaticsBiologicalBiological AssayBiological ProcessCardiorenal syndromeCell CycleCell NucleusCell ProliferationCell SeparationCellsCenters of Research ExcellenceClinicalComplementConsultationsCountryData SetDiseaseEnhancement TechnologyEnsureEquipmentFacultyFaculty WorkshopFlow CytometryFundingGene ExpressionGenerationsGeneticGenomicsGoalsHealthHigh PrevalenceHistorically Black Colleges and UniversitiesImmuneInfrastructureInstitutionInstructionMaintenanceMass Spectrum AnalysisMetabolic DiseasesMethodologyMississippiMolecularMolecular AnalysisMolecular BiologyMorbidity - disease rateNamesNucleic AcidsObesityPhasePhenotypePilot ProjectsPopulationProteomicsQuality ControlResearchResearch PersonnelResearch Project GrantsResourcesScientific Advances and AccomplishmentsScientistServicesSmall RNASortingStudentsSupervisionSystems BiologyTechnical ExpertiseTechniquesTechnologyTraining and EducationUnited StatesWorkXCL1 genecell typecomplex dataepigenomegenome sequencinggenomic dataglucose uptakeimprovedinsightinstrumentinstrumentationmeetingsmortalitymultidisciplinarymultiple omicsnext generation sequencingprogramsrelease of sequestered calcium ion into cytoplasmservice deliverysingle-cell RNA sequencingtraining opportunitytranscriptometranscriptome sequencingtranscriptomicsundergraduate studentwhole genome
项目摘要
CORE C – OMICS, BIOINFORMATICS AND FLOW CYTOMETRY CORE
PROJECT SUMMARY/ABSTRACT
The goal of the Cardiorenal and Metabolic Disease Research Center (CMDRC) COBRE is to bring together
a multidisciplinary group of basic, clinical, and population scientists to work synergistically on the theme of
cardiorenal and metabolic diseases. During Phases 1 and 2, the CMDRC - Core C provided COBRE
investigators and external researchers access to technical expertise and equipment to perform a wide variety
of molecular, genetic, and next generation sequencing studies. During Phases 1 and 2, Core C also made
major advances toward ensuring sustainability of its services. During Phase 3, the newly named Core C -
Omics, Bioinformatics and Flow Cytometry will extend its services and offer cutting-edge cellular and
molecular analysis through building on existing infrastructure supported in Phases 1 and 2 (Genomics and
Mass Spectrometry) to offer new cutting-edge omics methodologies as well as offer new capabilities through
recently acquired state-of-the-art cell sorting and flow cytometry equipment. The Omics and Bioinformatics
Sub-Core and Cell Sorting/Flow Cytometry Sub-Core will allow CMDRC investigators comprehensive
molecular or systems biology approaches to their research questions through detailed insight into cell-type
specific function, generation of “omics” datasets, and ultimately integration with detailed phenotype
information to provide greater depth and insight into biological processes associated with obesity, cardiorenal,
and metabolic diseases. Core C has four aims: (1) to provide CMDRC investigators access to technical
expertise and cutting-edge omics services, including next generation sequencing technologies (single cell
RNA sequencing, spatial transcriptomics) and facilitate proteomic technologies by leveraging existing IDeA
funded infrastructure (offer and coordinate proteomics services and through IDeA National Resource for
Quantitative Proteomics program); (2) to provide CMDRC investigators access to cutting-edge cell sorting
and flow cytometry expertise and services; (3) to provide education and training opportunities for students,
trainees, and faculty in omics technologies and flow cytometry; and (4) to provide continuous improvement in
existing assays and services and to enhance technological capabilities through acquisition of new cutting-
edge instrumentation that will assist in sustainability of the Core. Therefore, it is the objective of the CMDRC
- Core C to aid investigators in advancing scientific discovery in obesity, cardiorenal, and metabolic diseases
through application of state-of-the-art cell sorting, flow cytometry, and omics technologies to generate greater
insights into these diseases. Aside from CMDRC investigators, continued funding of the COBRE during Phase
3 will have a significant impact on providing external researchers (at other Mississippi undergraduate
institutions and Historically Black Colleges and Universities (HBCUs)) access to equipment and expertise that
would otherwise not be available in our region of the country.
核心组学、生物信息学和流式细胞术核心
项目总结/摘要
肾脏和代谢疾病研究中心(CMDRC)COBRE的目标是汇集
一个由基础、临床和人口科学家组成的多学科小组,协同工作,
心肾和代谢疾病。在第1和第2阶段,CMDRC -核心C提供了COBRE
调查人员和外部研究人员获得技术专长和设备,
分子、基因和下一代测序研究的重要性。在第1阶段和第2阶段,核心C还
在确保其服务的可持续性方面取得了重大进展。在第三阶段,新命名的核心C -
组学,生物信息学和流式细胞术将扩展其服务,并提供尖端的细胞和
通过在第1阶段和第2阶段支持的现有基础设施上进行分子分析(基因组学和
质谱)提供新的尖端组学方法,并通过
最近获得了最先进的细胞分选和流式细胞仪设备。组学与生物信息学
子核心和细胞分选/流式细胞术子核心将使CMDRC研究者能够全面了解
分子或系统生物学通过对细胞类型的详细了解来解决研究问题
特定功能,“组学”数据集的生成,以及最终与详细表型的整合
信息,以提供更深入的了解与肥胖,心肾,
和代谢性疾病。核心C有四个目标:(1)为CMDRC调查人员提供技术
专业知识和尖端的组学服务,包括下一代测序技术(单细胞
RNA测序、空间转录组学),并通过利用现有的IDEA
资助的基础设施(提供和协调蛋白质组学服务,并通过IDEA国家资源,
定量蛋白质组学计划);(2)为CMDRC研究人员提供尖端细胞分选技术
和流式细胞仪的专业知识和服务;(3)为学生提供教育和培训机会,
学员和教员在组学技术和流式细胞术;及(4)提供持续改进,
现有的分析和服务,并通过收购新的切割技术来提高技术能力,
边缘仪器,这将有助于核心的可持续性。因此,CMDRC的目标是
- 核心C帮助研究人员推进肥胖,心肾和代谢疾病的科学发现
通过应用最先进的细胞分选、流式细胞术和组学技术,
对这些疾病的认识。除了CMDRC调查员之外,COBRE在阶段期间的持续资助
3将对提供外部研究人员产生重大影响(在其他密西西比本科
机构和历史上的黑人学院和大学(HBCU))获得设备和专业知识,
否则在我国的这一地区将无法获得。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL R GARRETT其他文献
MICHAEL R GARRETT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL R GARRETT', 18)}}的其他基金
Core A- Administration, Education, and Mentoring
核心 A- 管理、教育和指导
- 批准号:
10553865 - 财政年份:2023
- 资助金额:
$ 22.41万 - 项目类别:
Genetic Targets of Hypertension End Organ Damage
高血压终末器官损伤的遗传靶标
- 批准号:
10198017 - 财政年份:2018
- 资助金额:
$ 22.41万 - 项目类别:
Genetic Targets of Hypertension End Organ Damage
高血压终末器官损伤的遗传靶标
- 批准号:
9920359 - 财政年份:2018
- 资助金额:
$ 22.41万 - 项目类别:
Core C - Genomics, Animal Models and Advanced Phenotyping Core
核心 C - 基因组学、动物模型和高级表型分析核心
- 批准号:
10403631 - 财政年份:2013
- 资助金额:
$ 22.41万 - 项目类别:
Core C - Genomics, Animal Models and Advanced Phenotyping Core
核心 C - 基因组学、动物模型和高级表型分析核心
- 批准号:
10159921 - 财政年份:2013
- 资助金额:
$ 22.41万 - 项目类别:
Genetics of Renal End Organ Damage in Hypertension
高血压肾终末器官损伤的遗传学
- 批准号:
8477235 - 财政年份:2009
- 资助金额:
$ 22.41万 - 项目类别:
Genetics of Renal End Organ Damage in Hypertension
高血压肾终末器官损伤的遗传学
- 批准号:
8289584 - 财政年份:2009
- 资助金额:
$ 22.41万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 22.41万 - 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 22.41万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 22.41万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 22.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 22.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 22.41万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 22.41万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 22.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 22.41万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 22.41万 - 项目类别:
Discovery Grants Program - Individual